Results 121 to 130 of about 12,730,863 (301)

Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide

, 2009
Celecoxib, an inhibitor of cyclooxygenase-2, is a promising novel antitumor agent with pleitropic mechanisms of action. Whereas this drug induces growth arrest and apoptosis of B-lymphoma cells, its effect against aggressive T-cell neoplasms remains to ...
Lindskog, Magnus,, Holmberg, Dan,, Pawelzik, Sven-Christian, Holmberg, Dan, Johansson, Ann-Sofie,, Jakobsson, Per-Johan, Pawelzik, Sven-Christian,, Jakobsson, Per-Johan,, Johansson, Ann-Sofie, Larefalk, Åsa,, Larefalk, Åsa   +10 more
core   +1 more source

Comparison of outcomes after DA‐EPOCH‐R or GMALL high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort

British Journal of Haematology, EarlyView.
In this retrospective cohort of adult Burkitt lymphoma, DA‐EPOCH‐R showed no signal of inferior survival or relapse risk compared with GMALL‐based high‐intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Eduard Schulz, Florian Posch, Kristina Friedrich, Peter Neumeister, Katharina T. Prochazka   +4 more
wiley   +1 more source

Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma

Zhongliu Fangzhi Yanjiu, 2018
Objective To analyze clinical features of lymphoblastic lymphoma(LBL), compare clinical and prognostic characteristics of B lymphoblasts lymphoma (B-LBL) and T lymphoblasts lymphoma (T-LBL), and the prognosis of various chemotherapy regimens on LBL ...
YUAN Ying, ZANG Li, YUE Zhijie, ZHANG Yizhuo, WANG Xiaofang   +4 more
doaj   +1 more source

B-Lymphoblastic Lymphoma Isolated to the Testes: A Case Report and Review of Literature. [PDF]

Cureus, 2023
Daccache A, Feghali E, Chedid K, Saad K, Staddon J.   +4 more
europepmc   +1 more source

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests

British Journal of Haematology, EarlyView.
Summary Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work‐up in primary care.
Mathilde Egelund Christensen, Michael Charles Sachs, William Grant Dunn, Gustav Jonzon, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson, Kirsten Groenbaek, George Vassiliou, Christen Lykkegaard Andersen   +9 more
wiley   +1 more source

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. [PDF]

, 2011
Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL).
Graham P. Collins, Liggins, Amanda P., Liggins, AP, Lawrie, Charles H., Banham, Alison H., Pulford, Karen, Pulford Karen, Christopher D. O. Cooper, Cooper Christopher D. O., Christian S. R. Hatton, Hatton, Christian S.R., Cooper, CD, Hatton Christian S. R., Lawrie, CH, Liggins Amanda P., Banham, Alison, Christopher D O Cooper, Hatton, CS, Banham, AH, Collins, GP, Charles H Lawrie, Pulford, K, Amanda P Liggins, Banham Alison H., Karen Pulford, Charles H. Lawrie, Amanda P. Liggins, Collins Graham P., Graham P Collins, Collins, Graham P., Alison H Banham, Christian S R Hatton, Lawrie Charles H., Cooper, Christopher D.O., Alison H. Banham   +34 more
core   +2 more sources

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma [PDF]

, 2011
Background: Mantle cell lymphoma (MCL) is genetically characterized by the t(11;14)(q13;q32) translocation and a high number of secondary chromosomal alterations. The contribution of DNA methylation to MCL lymphomagenesis is not well known.
Campo Elías, Fernandez, Veronica, Sílvia Beà, Magda Pinyol, Hernández Luis, Beà Bobet, Sílvia M., Fernàndez Verònica, Jares, Pedro, Anna Enjuanes, Andreas Rosenwald, Pinyol Magda, Verònica Fernàndez, Rosenwald, Andreas, Pinyol, Magda, Pedro Jares, German Ott, López-Guillermo Armando, Enjuanes Anna, Bea, Silvia, Hernández, Luis, López Guillermo, Armando, Beà Sílvia, Rosenwald Andreas, Fernàndez Pascual, Verònica, Armando López-Guillermo, Navarro, Alba, Jares Pedro, Lopez-Guillermo, Armando, Ott, German, Jares Gerboles, Pedro, Luis Hernández, Campo Güerri, Elias, Navarro Alba, Elías Campo, Campo, Elias, Alba Navarro, Enjuanes, Anna, Ott German   +37 more
core   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Leucemia Linfoblástica aguda recidivada tratada com rituximab: relato de caso e revisão de literatura. [PDF]

, 2007
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Borbinhão, Rodrigo Widholzer
core